Business Description
Fusion Antibodies PLC
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Description
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.07 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.26 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 12.11 | |||||
| Beneish M-Score | -4.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.6 | |||||
| 3-Year EBITDA Growth Rate | 19.3 | |||||
| 3-Year EPS without NRI Growth Rate | -38.4 | |||||
| 3-Year FCF Growth Rate | -36.9 | |||||
| 3-Year Book Growth Rate | -14.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 8.97 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.7 | |||||
| 9-Day RSI | 66.9 | |||||
| 14-Day RSI | 70.26 | |||||
| 6-1 Month Momentum % | -45.68 | |||||
| 12-1 Month Momentum % | -63.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.09 | |||||
| Quick Ratio | 3.57 | |||||
| Cash Ratio | 1.84 | |||||
| Days Inventory | 73.29 | |||||
| Days Sales Outstanding | 90.01 | |||||
| Days Payable | 98.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.03 | |||||
| Operating Margin % | -28.93 | |||||
| Net Margin % | -64.07 | |||||
| ROE % | -55.23 | |||||
| ROA % | -46.32 | |||||
| ROIC % | -95.61 | |||||
| ROC (Joel Greenblatt) % | -55.92 | |||||
| ROCE % | -23.98 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.67 | |||||
| PB Ratio | 5.18 | |||||
| Price-to-Tangible-Book | 5.18 | |||||
| EV-to-EBIT | -15.22 | |||||
| EV-to-EBITDA | -34.43 | |||||
| EV-to-Revenue | 4.31 | |||||
| EV-to-Forward-Revenue | 3.22 | |||||
| EV-to-FCF | -16.97 | |||||
| Price-to-Net-Current-Asset-Value | 6.54 | |||||
| Price-to-Net-Cash | 28.33 | |||||
| Earnings Yield (Greenblatt) % | -6.57 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 4.701 | ||
| EPS (TTM) (£) | -0.118 | ||
| Beta | 0.59 | ||
| Volatility % | 64.86 | ||
| 14-Day RSI | 70.26 | ||
| 14-Day ATR (£) | 0.092218 | ||
| 20-Day SMA (£) | 0.643 | ||
| 12-1 Month Momentum % | -63.33 | ||
| 52-Week Range (£) | 0.36 - 1.38 | ||
| Shares Outstanding (Mil) | 26.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fusion Antibodies PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||